What happened, in summary

Jill already knew the fear of lung cancer before her own diagnosis. Her father died at 41, only 3 months after being diagnosed, and her mother died at 54, 6 months after her diagnosis. Because of that family history, Jill had periodic CT scans even though she had no symptoms. One scan found a nodule in her lung, and the diagnosis was especially frightening because her children were 6, 8, 10, and 12. Her treatment path centered on biomarker testing. Waiting for results was difficult, but the testing identified a driver mutation and helped guide treatment toward her cancer rather than a generic plan. She began pill-based targeted therapy, with regular monitoring about every 3 months, and the treatment advances gave her years to raise her children, reach college drop-offs, make memories, and become an advocate. Later, after progression and metastases in the pleura, chemotherapy was added while she continued targeted therapy. As of May 2026, Jill had lived 17 years with NSCLC. She also helped build the EGFR Resisters community in 2017, offering patients support, information, and a place to connect with others who understood the emotional weight of living with lung cancer. Her story also highlights that lung cancer can be silent, so family history, subtle body changes, and appropriate testing can matter.